Results 51 to 60 of about 1,870 (108)

Oncolytic virus VG161 offers new hope for refractory liver cancer. [PDF]

Front Oncol
Li J, Zhou H, Wang X, Huang K, Wang Y.
europepmc   +1 more source

Cracking the shield: oncolytic viruses versus the tumor-immune fortress. [PDF]

Cancer Cell Int
El-Derby AM, Salem NT, Hesham N, Salem TZ.   +3 more
europepmc   +1 more source

Emerging Oncolytic Viruses: Beyond Adenoviruses and Herpes Simplex Virus. [PDF]

J Cancer
Chokkakula S, Yin C, Yang B, Chong S, Pathakumari B, Zhang YQ, Nirmala PV, Lai KW, Naveen B, Tang Q.   +9 more
europepmc   +1 more source

Faculty Opinions recommendation of Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2013
openaire   +2 more sources

A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors

Annals of Oncology, 2017
M. Toulmonde, S. Cousin, A. Bessede, M. Homerin, N. Stojkowitz, M. Lusky, M. Pulido, A. Italiano   +7 more
openaire   +1 more source

Research progress and development potential of oncolytic vaccinia virus. [PDF]

Chin Med J (Engl)
Zhang X, He J, Shao Y.
europepmc   +1 more source

402 JX-594, a targeted multi-mechanistic oncolytic poxvirus, infects tumor vasculature and causes acute tumor vascular disruption and necrosis in advanced cancer patients

European Journal of Cancer Supplements, 2010
C. Breitbach, R. Patt, N. De Silva, K. Parato, M. Daneshmand, T. Hickman, J.C. Bell, D.H. Kirn   +7 more
openaire   +1 more source

Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives. [PDF]

Vaccines (Basel)
Muthukutty P, Heo J, Yoo SY.
europepmc   +1 more source

Gene Therapy Strategies for Hepatocellular Carcinoma (HCC): Current Landscape and Future Directions. [PDF]

Cancers (Basel)
Ermi AG, Younis RM, Rodriguez K, Sarkar D.   +3 more
europepmc   +1 more source

50. Demonstration of Safety and Antitumoral Activity of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, Following Intravenous Infusion and/or Intratumoral Injections in Patients with Refractory Metastatic Cancers [PDF]

Molecular Therapy, 2011
openaire   +1 more source